ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,811.80
0.00%
S&P ASX All Technology
3,103.10
0.00%
Brent Oil
81.31
-0.27%
US Dollar vs AUD
1.51425
0.23%
Bitcoin
67,499.85
-2.32%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. USOTC
  6. PharmaTher Holdings Ltd (QB) (PHRRF)

  7. PharmaTher Holdings Ltd (QB) (PHRRF) News

PHRRF

PharmaTher (QB) (PHRRF)

PharmaTher Holdings Ltd (QB)
Date:
Sort by:
 Showing the most relevant articles for your search:USOTC:PHRRF
DateTimeSourceHeadlineSymbolCompany
19/09/202220:31TipRanksAnalysts Offer Insights on Healthcare Companies: PharmaTher Holdings Ltd (OtherPHRRF), Rezolute (RZLT) and ADC Therapeutics (ADCT)USOTC:PHRRFPharmaTher Holdings Ltd (QB)
15/06/202219:03TipRanksH.C. Wainwright Keeps a Buy Rating on PharmaTher Holdings Ltd (PHRRF)USOTC:PHRRFPharmaTher Holdings Ltd (QB)
22/11/202122:16TipRanksH.C. Wainwright Thinks NPharmaTher’s Stock is Going to RecoverUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
12/11/202102:00InvestorsHub NewsWirePharmaTher Announces Positive Research Results for Psilocybin Microneedle PatchUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
03/11/202123:03InvestorsHub NewsWirePharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle PatchUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
19/10/202122:07InvestorsHub NewsWirePharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine ProductsUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
14/10/202100:20InvestorsHub NewsWirePharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain SyndromeUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
22/09/202100:19InvestorsHub NewsWirePharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded FundUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
13/09/202123:03InvestorsHub NewsWirePharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022USOTC:PHRRFPharmaTher Holdings Ltd (QB)
04/08/202122:15InvestorsHub NewsWirePharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral SclerosisUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
21/07/202122:19InvestorsHub NewsWirePharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine FormulationUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
17/06/202101:14InvestorsHub NewsWirePharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat DepressionUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
25/05/202122:45InvestorsHub NewsWirePharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's DiseaseUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
17/05/202122:02InvestorsHub NewsWirePharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's DiseaseUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
27/04/202121:47InvestorsHub NewsWirePharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics..ContUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
20/04/202122:00InvestorsHub NewsWirePharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical TrialUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
16/04/202101:32InvestorsHub NewsWirePharmaTher Provides Update on Psychedelic Product ProgramsUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
02/03/202123:34InvestorsHub NewsWirePharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou....ContUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
18/02/202102:11InvestorsHub NewsWirePharmaTher Announces Sale of Psilocybin ProgramUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
05/02/202100:21InvestorsHub NewsWirePharmaTher Announces Successful Completion of Pre-IND Meeting with FDAUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
02/02/202100:19InvestorsHub NewsWirePharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver KetamineUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
20/01/202100:07InvestorsHub NewsWirePharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine FormulationUSOTC:PHRRFPharmaTher Holdings Ltd (QB)
 Showing the most relevant articles for your search:USOTC:PHRRF

Your Recent History

EU
BPCSJ
BPCE Floating Rate due 2...
BIT
UC915F
Unicredit Bank
LSE
0I00
TSXV
CELL
Grid Battery Metals
BIT
UC63GC
Unicredit Bank
NASDAQ
FXZIKX
Strong Foundation Portfo...
USOTC
FMEGF
Farmers Edge (PK)
EU
0621T
0621T
USOTC
CZBT
Citizens Bancorp of Virg... (PK)
BOV
BWOR39
Xtrackers Msci World Uci...
BIT
UB60T9
Unicredit Bank
BIT
GGB
Exchange Traded Fund Ubs...
BITMOT
984986
Belgium Tf 3,45% Gn43 Eur
ASX
PTXNC
Prescient Therapeutics
EU
INCNY
Hsbc CNY iNav
LSE
61VM
Investec Bnk 25
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved